

# Gilles Wandeler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4923070/publications.pdf>

Version: 2024-02-01

109  
papers

4,550  
citations

218592

26  
h-index

110317

64  
g-index

111  
all docs

111  
docs citations

111  
times ranked

5889  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	0.9	69
2	The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	1.0	8
3	Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 135-145.	2.4	5
4	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	1.0	2
5	HCV reinfection after HCV therapy among HIV/HCV coinfecting individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	1.0	4
6	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. <i>Viruses</i> , 2022, 14, 784.	1.5	2
7	Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. <i>Liver International</i> , 2021, 41, 710-719.	1.9	15
8	Hepatitis C among men who have sex with men: knowing your epidemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 5-6.	3.7	5
9	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfecting Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 248-257.	0.9	3
10	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	2.0	66
11	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	1.1	0
12	Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. <i>Current Epidemiology Reports</i> , 2021, 8, 89-96.	1.1	9
13	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 295.	1.0	11
14	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
15	Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal. <i>Journal of Viral Hepatitis</i> , 2021, , .	1.0	3
16	Clinical outcomes in persons coinfecting with HIV and HCV: Impact of HCV treatment. <i>Clinical Infectious Diseases</i> , 2020, 70, 2131-2140.	2.9	9
17	High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfecting Patients on Antiretroviral Therapy in Zambia. <i>Journal of Infectious Diseases</i> , 2020, 221, 218-222.	1.9	29
18	Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study. <i>Heliyon</i> , 2020, 6, e04534.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunctionâ€”A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 227-232.	0.9	13
20	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	1.9	22
21	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 240-250.	0.9	24
22	Hepatitis D virus: is it all in the family?. <i>Gut</i> , 2020, 69, 1162-1163.	6.1	0
23	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLâ€™HIV trial. <i>PLoS Medicine</i> , 2020, 17, e1003421.	3.9	23
24	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. <i>PLoS Medicine</i> , 2020, 17, e1003397.	3.9	7
25	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa470.	0.4	1
26	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
27	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
28	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
29	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
30	Title is missing!. , 2020, 17, e1003421.		0
31	Title is missing!. , 2020, 17, e1003421.		0
32	Title is missing!. , 2020, 17, e1003421.		0
33	Title is missing!. , 2020, 17, e1003421.		0
34	Title is missing!. , 2020, 17, e1003421.		0
35	Title is missing!. , 2020, 17, e1003421.		0
36	Hepatitis B Therapy as HIV Prevention in Africa: A Case Series From Zambia. <i>Hepatology</i> , 2019, 69, 458-460.	3.6	0

#	ARTICLE	IF	CITATIONS
37	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.4	28
38	Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa. <i>PLoS Computational Biology</i> , 2019, 15, e1007083.	1.5	11
39	A closer look at the spectrum of drug-induced liver injury in sub-Saharan Africa. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 875-883.	1.3	4
40	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 834.	1.3	6
41	Research priorities to inform "Treat All" policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA). <i>Journal of the International AIDS Society</i> , 2019, 22, e25218.	1.2	32
42	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	6.3	627
43	Clusters of Sexual Behavior in Human Immunodeficiency Virus-positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. <i>Clinical Infectious Diseases</i> , 2019, 70, 416-424.	2.9	9
44	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. <i>Journal of Hepatology</i> , 2019, 71, 274-280.	1.8	31
45	Modelling the impact of different testing strategies for HCV infection in Switzerland. <i>Journal of Virus Eradication</i> , 2019, 5, 191-203.	0.3	2
46	Fewer pills do not mean fewer drug-drug interactions. <i>Aids</i> , 2018, 32, 676-678.	1.0	4
47	Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 1846-1857.	2.9	53
48	Field performance of the Determine HBsAg point-of-care test for diagnosis of hepatitis B virus co-infection among HIV patients in Zambia. <i>Journal of Clinical Virology</i> , 2018, 98, 5-7.	1.6	15
49	Issues with measuring hepatitis prevalence in resource-limited settings. <i>Lancet, The</i> , 2018, 391, 835-836.	6.3	2
50	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 413-416.	0.9	2
51	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1359.	0.8	31
52	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. <i>Journal of Virus Eradication</i> , 2018, 4, 55-58.	0.3	25
53	Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy275.	0.4	5
54	High prevalence of binge drinking among people living with HIV in four African countries. <i>Journal of the International AIDS Society</i> , 2018, 21, e25202.	1.2	26

#	ARTICLE	IF	CITATIONS
55	The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Review of Gastroenterology and Hepatology, 2018, 12, 537-546.	1.4	15
56	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. American Journal of Epidemiology, 2018, 187, 1990-2001.	1.6	8
57	No Impact of Hepatitis B Virus Infection on Early Mortality Among Human Immunodeficiency Virus-Infected Patients in Southern Africa. Clinical Infectious Diseases, 2018, 67, 1310-1311.	2.9	3
58	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy154.	0.4	17
59	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. F1000Research, 2018, 7, 1359.	0.8	24
60	Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver International, 2018, 38, 424-431.	1.9	22
61	Chronic hepatitis B virus mono-infection at a university hospital in Zambia. World Journal of Hepatology, 2018, 10, 622-628.	0.8	4
62	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication, 2018, 4, 55-58.	0.3	12
63	Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies. Liver International, 2017, 37, 1116-1121.	1.9	23
64	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases, 2017, 64, 1275-1278.	2.9	23
65	Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study. Journal of the International AIDS Society, 2017, 20, 21424.	1.2	33
66	Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action. Global Health Action, 2017, 10, 1359923.	0.7	10
67	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 2017, 66, 297-303.	1.8	101
68	The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment. Open Forum Infectious Diseases, 2017, 4, ofx070.	0.4	34
69	Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. BMC Infectious Diseases, 2017, 17, 466.	1.3	17
70	Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa. BMC Infectious Diseases, 2017, 17, 706.	1.3	31
71	Prevention and Care of Hepatitis B in Senegal; Awareness and Attitudes of Medical Practitioners. American Journal of Tropical Medicine and Hygiene, 2017, 97, 389-395.	0.6	16
72	Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clinical Infectious Diseases, 2017, 64, 1343-1349.	2.9	43

#	ARTICLE	IF	CITATIONS
73	Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 20711.	1.2	19
74	HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. <i>BMC Infectious Diseases</i> , 2016, 16, 249.	1.3	33
75	The J-Curve in HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 302-309.	0.9	14
76	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw162.	0.4	18
77	Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. <i>International Journal of Infectious Diseases</i> , 2016, 46, 8-10.	1.5	17
78	Association between hepatitis B co-infection and elevated liver stiffness among HIV-infected adults in Lusaka, Zambia. <i>Tropical Medicine and International Health</i> , 2016, 21, 1435-1441.	1.0	15
79	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016, 64, 1856-1869.	3.6	82
80	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	3.8	1,076
81	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016, 51, 97-102.	1.5	18
82	Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 492-500.	1.5	274
83	Retention in care of HIV-infected pregnant and lactating women starting ART under Option B+ in rural Mozambique. <i>Tropical Medicine and International Health</i> , 2016, 21, 1003-1012.	1.0	43
84	Absence of Active Hepatitis C Virus Infection in Human Immunodeficiency Virus Clinics in Zambia and Mozambique. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw049.	0.4	10
85	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Journal of Hepatology</i> , 2016, 65, 26-32.	1.8	26
86	Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. <i>PLoS ONE</i> , 2016, 11, e0152043.	1.1	25
87	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. <i>Swiss Medical Weekly</i> , 2016, 146, w14348.	0.8	31
88	Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	1.7	5
89	Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 483.	1.3	17
90	Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. <i>Liver International</i> , 2015, 35, 1886-1892.	1.9	15

#	ARTICLE	IF	CITATIONS
91	Response to "Is AST-to-platelet ratio index a reliable tool in HIV patients in Africa?"™. <i>Liver International</i> , 2015, 35, 2060-2060.	1.9	0
92	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	1.2	52
93	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv026.	0.4	20
94	Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples. <i>Journal of Clinical Virology</i> , 2015, 69, 33-35.	1.6	10
95	Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. <i>Lancet HIV</i> , 2015, 2, e271-e278.	2.1	98
96	Hepatitis B viral load in dried blood spots: A validation study in Zambia. <i>Journal of Clinical Virology</i> , 2015, 72, 20-24.	1.6	25
97	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015, 15, 79.	0.8	18
98	Hepatitis C: a changing epidemic. <i>Swiss Medical Weekly</i> , 2015, 145, w14093.	0.8	32
99	Chronic Hepatitis B Virus Coinfection Is Associated With Renal Impairment Among Zambian HIV-Infected Adults. <i>Clinical Infectious Diseases</i> , 2014, 59, 1757-1760.	2.9	12
100	Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ("Option B+"™) in Malawi. <i>Aids</i> , 2014, 28, 589-598.	1.0	317
101	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2013, 208, 1454-1458.	1.9	67
102	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 178, 877-884.	1.6	116
103	Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. <i>Antiviral Therapy</i> , 2013, 19, 521-525.	0.6	4
104	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. <i>Aids</i> , 2013, 27, 2225-2232.	1.0	13
105	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1408-1416.	2.9	225
106	Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, e9-e16.	0.9	68
107	Tenofovir in Second-Line ART in Zambia and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 41-48.	0.9	12
108	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011, 6, e27903.	1.1	21

#	ARTICLE	IF	CITATIONS
109	Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors. F1000Research, 0, 8, 1400.	0.8	1